Crypto Pioneer Says: “The last crypto bull market has begun.”

Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.

Click here if you’d like to learn more about these five cryptos…

Michael Zinda Biography and Net Worth

EVP of Repare Therapeutics

Michael Zinda, Ph.D. has served as our Executive Vice President, Chief Scientific Officer since May 2019 and previously served as Executive Vice President, Head of Research and Development of our U.S. subsidiary, Repare Therapeutics USA Inc., from June 2017 to May 2019. Prior to joining us, he spent 16 years at AstraZeneca from 2001 to May 2017, where he obtained the position of Executive Director, Head of Cancer Bioscience.

In this role, Dr. Zinda served on the global science leadership team, oncology research board and the Acerta research and early development teams accountable for strategy, key collaborations/partnerships and delivery of an innovative portfolio of patient-centric drug discovery programs.

Dr. Zinda holds a B.Sc. in biology from Minnesota State University Moorhead and a Ph.D. in molecular biology from Vanderbilt University. He received his post-doctoral training at Princeton University and Eli Lilly & Company.

What is Michael Zinda's net worth?: The estimated net worth of Michael Zinda is at least $255,273.40 as of April 1st, 2024. Dr. Zinda owns 71,908 shares of Repare Therapeutics stock worth more than $255,273 as of May 19th. This net worth estimate does not reflect any other investments that Dr. Zinda may own. Additionally, Dr. Zinda receives an annual salary of $641,530.00 as EVP at Repare Therapeutics. Learn More about Michael Zinda's net worth.
How old is Michael Zinda?: Dr. Zinda is currently 53 years old. There are 3 older executives and no younger executives at Repare Therapeutics. The oldest executive at Repare Therapeutics is Dr. Maria Koehler M.D., Ph.D., Executive VP & Chief Medical Officer, who is 67 years old. Learn More on Michael Zinda's age.
What is Michael Zinda's salary?: As the EVP of Repare Therapeutics Inc., Dr. Zinda earns $641,530.00 per year. There are 2 executives that earn more than Dr. Zinda. The highest earning executive at Repare Therapeutics is Mr. Lloyd Mitchell Segal, President, CEO & Director, who commands a salary of $932,180.00 per year. Learn More on Michael Zinda's salary.
How do I contact Michael Zinda?: The corporate mailing address for Dr. Zinda and other Repare Therapeutics executives is 7210 Frederick-Banting Suite 100, St-Laurent A8, H4S 2A1. Repare Therapeutics can also be reached via phone at 857-412-7018 and via email at [email protected]. Learn More on Michael Zinda's contact information.
Has Michael Zinda been buying or selling shares of Repare Therapeutics?: During the last quarter, Michael Zinda has sold $1,910.60 of Repare Therapeutics stock. Most recently, Michael Zinda sold 410 shares of the business's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $4.66, for a transaction totalling $1,910.60. Following the completion of the sale, the executive vice president now directly owns 71,908 shares of the company's stock, valued at $335,091.28. Learn More on Michael Zinda's trading history.
Who are Repare Therapeutics' active insiders?: Repare Therapeutics' insider roster includes David Bonita (Director), Thomas Civik (Director), Todd Foley (Director), Ansbert Gadicke (Major Shareholder), Lloyd Segal (CEO), and Michael Zinda (EVP). Learn More on Repare Therapeutics' active insiders.
Are insiders buying or selling shares of Repare Therapeutics?: In the last twelve months, Repare Therapeutics insiders bought shares 2 times. They purchased a total of 1,715,265 shares worth more than $7,479,132.40. In the last twelve months, insiders at the sold shares 10 times. They sold a total of 12,740 shares worth more than $68,485.47. The most recent insider tranaction occured on April, 1st when CEO Lloyd Mitchell Segal sold 2,491 shares worth more than $11,533.33. Insiders at Repare Therapeutics own 28.5% of the company. Learn More about insider trades at Repare Therapeutics.
Information on this page was last updated on 4/1/2024.

Michael Zinda Insider Trading History at Repare Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/1/2024	Sell	410	$4.66	$1,910.60	71,908
3/27/2024	Sell	450	$4.62	$2,079.00	72,768
3/25/2024	Sell	450	$4.78	$2,151.00	73,668
6/6/2023	Sell	1,200	$12.04	$14,448.00	69,391
11/15/2021	Sell	20,000	$27.33	$546,600.00
5/17/2021	Sell	15,000	$32.71	$490,650.00	49,801
12/29/2020	Sell	34,744	$33.92	$1,178,516.48	85,277
12/23/2020	Sell	16,235	$33.66	$546,470.10	100,935
12/21/2020	Sell	40,000	$33.08	$1,323,200.00	125,229
12/18/2020	Sell	17,277	$34.94	$603,658.38	92,105
12/16/2020	Sell	8,956	$35.26	$315,788.56	92,105

Michael Zinda Buying and Selling Activity at Repare Therapeutics

Repare Therapeutics Company Overview

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Today's Range

Now: $3.55

$3.45

$3.66

50 Day Range

MA: $4.01

$3.02

$5.40

2 Week Range

Now: $3.55

$2.98

$13.85

Volume

219,390 shs

Average Volume

407,916 shs

Market Capitalization

$150.66 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Crypto Pioneer Says: “The last crypto bull market has begun.”

From InvestorPlace | Ad

Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.

Click here if you’d like to learn more about these five cryptos…

Michael Zinda Biography and Net Worth

What is Michael Zinda's net worth?

How old is Michael Zinda?

What is Michael Zinda's salary?

How do I contact Michael Zinda?

Has Michael Zinda been buying or selling shares of Repare Therapeutics?

Who are Repare Therapeutics' active insiders?

Are insiders buying or selling shares of Repare Therapeutics?